Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL).

This collaboration will leverage the existing commercial product systems of both parties to jointly build a product matrix in the field of biomaterials, while actively exploring new product opportunities through the 510(K) regulatory pathway. The partnership will integrate Celularity's innovative technologies in cell therapy with Nexgel's hydrogel material platform advantages, aiming to accelerate the implementation of biomaterial solutions for medical scenarios such as wound repair and tissue regeneration. The two sides plan to complement each other's resources to promote market expansion of already launched products and develop a new generation of medical products via the 510(K) exemption route. Both parties stated that this strategic partnership will strengthen their competitiveness in the biomaterials market and provide a more comprehensive product portfolio for the medical industry. Through collaborative innovation and commercial operations, they look forward to opening new growth paths and enhancing their influence in the field of regenerative medicine.